The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...
Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function. This tool will be launched as ...
DelveInsight’s, “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy ...
We have moved health technology evaluation 28 to become HealthTech guidance 753. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...
"Acute Lymphocytic Leukemia (ALL) Pipeline Insight 2025"DelveInsight's,“Acute Lymphocytic Leukemia (ALL) – Pipeline Insight, 2025,” report provides comprehensive insights about 125+ companies and 130+ ...
DelveInsight’s, “Acute Lymphocytic Leukemia (ALL) – Pipeline Insight, 2025,” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Acute Lymphocytic Leukemia (ALL) ...
"Chronic Inducible Urticaria Pipeline Analysis""DelveInsight's,“Chronic Inducible Urticaria - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in ...
This, of course, does not indicate that there is no need for better proposals that could improve our ability to diagnose CLL and, more importantly, to better classify an imprecise group of B-LPD named ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results